• Home
• Conference Coverage
• Event Calendar
• UroToday International Journal
• Advanced Search

IPF 2009 - Treatment of metastatic prostate cancer: New strategies - Session Highlights

IZMIR, TURKEY (UroToday.com) - Provenge has been shown to improve the survival of men with castrate resistant prostate cancer (CRPC).

Login to read more...

Written by David P. Wood, MD, a Contributing Editor with UroToday.

UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810 About The Editors | About Us | Contact Us | Report an Inaccuracy | Sponsorship Opportunities | Terms of Use Privacy Policy | © 2009 UroToday ® All Rights Reserved